文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

用简约机器学习模型量化肺炎与脓毒症的免疫失调:跨医疗场景的多队列分析及氢化可的松随机对照试验再分析

Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2026-03-16
一句话结论基于降钙素原、可溶性TREM-1和IL-6的三生物标志物框架可量化免疫失调程度,在CAPE COD试验再分析中,氢化可的松仅对模型判定为重度免疫失调者显示生存获益。

该多队列分析在三个独立队列的398例社区获得性肺炎患者中,基于35种血浆生物标志物构建免疫失调连续评分(cDIP,0-1)和三个离散阶段(DIP1-3),并开发三生物标志物(降钙素原、可溶性TREM-1、IL-6)机器学习模型预测DIP阶段(准确率91.2%)和cDIP(均方根误差0.056)。模型在五个外部队列(n=1191)中验证。cDIP每增加10%,死亡风险OR 1.26(95%CI 1.13-1.40,p<0.0001),继发感染OR 1.50(95%CI 1.22-1.93,p=0.0005),独立于临床严重程度。CAPE COD试验再分析显示氢化可的松的生存获益仅见于DIP3(30天死亡率OR 0.25,95%CI 0.05-0.85,p=0.042)或cDIP≥0.63(OR 0.21,95%CI 0.10-0.72,p=0.011)者,伴免疫恢复更快(时间×治疗交互p<0.0001);按临床严重程度分层未见效应修饰。

要点

  • 三生物标志物模型(降钙素原、可溶性TREM-1、IL-6)预测35种标志物衍生的免疫失调阶段准确率91.2%,cDIP均方根误差0.056,已在五个外部队列(n=1191)验证。
  • cDIP每增加10%,死亡风险OR 1.26(95%CI 1.13-1.40,p<0.0001),继发感染OR 1.50(95%CI 1.22-1.93,p=0.0005),独立于临床严重程度。
  • CAPE COD试验再分析中,氢化可的松的30天生存获益仅见于DIP3(OR 0.25,95%CI 0.05-0.85,p=0.042)或cDIP≥0.63(OR 0.21,95%CI 0.10-0.72,p=0.011)者。
  • 按临床严重程度分层未观察到氢化可的松的效应修饰,提示临床严重度不能替代免疫失调程度来筛选可能获益者。
  • 重度免疫失调者使用氢化可的松后免疫恢复更快(时间×治疗交互p<0.0001)。

适用人群与场景

  • 社区获得性肺炎(CAP)患者,覆盖急诊科、普通病房和重症监护室不同医疗场景及不同疾病严重程度。
  • 外部验证队列涵盖不同感染类型、严重程度和医疗场景(n=1191)。
  • CAPE COD随机对照试验再分析人群为重症CAP患者。

诊断标准与关键阈值

  • 免疫失调离散阶段DIP1-3由35种血浆生物标志物的无监督轨迹推断分析确定。
  • 连续免疫失调评分cDIP范围为0-1。
  • 三生物标志物机器学习模型以降钙素原、可溶性TREM-1和IL-6预测DIP阶段和cDIP。
  • CAPE COD再分析中用于分层氢化可的松疗效的阈值为cDIP≥0.63。

研究设计与关键结果

  • 多队列分析与随机对照试验再分析:在三个独立队列的398例CAP患者中,基于35种血浆生物标志物将免疫失调组织为从轻到重的连续谱,得出三个失调阶段(DIP1-3)和连续评分cDIP。
  • 临床严重程度被证明是免疫失调的不充分替代指标。
  • 三生物标志物机器学习框架(降钙素原、可溶性TREM-1、IL-6)准确预测35种标志物衍生的失调程度:DIP阶段准确率91.2%,cDIP均方根误差0.056。
  • 免疫失调加重与死亡率逐渐升高相关:cDIP每增加10%,死亡率OR 1.26(95%CI 1.13-1.40,p<0.0001),继发感染OR 1.50(95%CI 1.22-1.93,p=0.0005),独立于临床严重程度。
  • 三生物标志物工具在五个外部队列中验证,涵盖不同感染、严重程度和医疗场景(n=1191)。
  • CAPE COD试验再分析:氢化可的松仅在模型判定为重度免疫失调者中带来生存获益(30天死亡率:DIP3 OR 0.25,95%CI 0.05-0.85,p=0.042;cDIP≥0.63 OR 0.21,95%CI 0.10-0.72,p=0.011),并伴免疫恢复更快(时间×治疗交互p<0.0001)。
  • 按临床严重程度分层未观察到效应修饰。

证据类型、等级与局限

  • 研究类型:多队列分析及随机对照试验(CAPE COD,NCT02517489)再分析。
  • CAPE COD试验再分析为事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,所提供公开可用的三生物标志物框架可用于确定宿主反应失调程度,对精准指导免疫调节治疗具有潜在价值。
  • CAPE COD再分析提示,氢化可的松的生存获益仅见于模型判定为重度免疫失调(DIP3或cDIP≥0.63)的重症CAP患者,按临床严重程度分层未见此效应修饰。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Sepsis is a dysregulated host response to infection resulting in life-threatening organ failure. Although immune dysregulation is central to the sepsis definition, immunomodulation trials enrol participants based on clinical severity, not the extent of dysregulation, which could contribute to treatment heterogeneity. A pragmatic way to quantify immune dysregulation could improve prognostication, help to evaluate treatment responses, and identify individuals most likely to benefit from immunomodulation. We aimed to construct a parsimonious machine-learning tool that defines and quantifies immune dysregulation, thereby supporting biologically informed immunomodulation.

METHODS: In this multicohort analysis and reanalysis of a randomised controlled trial, the primary objective was to derive and validate a categorical and continuous immune dysregulation score that is independent of clinical presentation or outcome. We measured 35 plasma biomarkers reflecting key host response domains in individuals with community-acquired pneumonia (CAP) across different care settings (emergency department, general ward, and intensive care unit) and disease severities using data from three independent cohorts. We applied unsupervised trajectory inference analysis to identify an immune dysregulation gradient captured as discrete immune dysregulation stages (Dysregulated Immune Profile [DIP]) and a continuous score (cDIP; 0-1). We developed two parsimonious machine-learning models to predict the DIP stages and cDIP scores based on 35 biomarkers, and validated their ability to capture immune dysregulation and predict clinical outcomes in five independent cohorts. On the basis of our hypothesis that only individuals with severe immune dysregulation benefit from immunomodulation, we carried out a post-hoc analysis of a randomised trial evaluating hydrocortisone in severe CAP (CAPE COD trial, NCT02517489), assessing treatment effects across DIP stages and the cDIP continuum, and how hydrocortisone influenced dysregulation trajectories over time.

FINDINGS: We organised 398 participants with CAP along a continuum of immune dysregulation from mild to severe on the basis of 35 plasma biomarkers, yielding three dysregulation stages (DIP1-3) and a continuous score (cDIP). Clinical severity proved to be an inadequate proxy for immune dysregulation. A three-biomarker machine-learning framework (procalcitonin, soluble TREM-1, and IL-6) accurately predicted the degree of dysregulation derived from 35 biomarkers (DIP stage accuracy 91·2%; cDIP root mean square error 0·056). Although the framework was not designed for outcome prediction, increased immune dysregulation-reflected in DIP and cDIP-was associated with a gradual rise in mortality (cDIP odds ratio [OR] 1·26 [95% CI 1·13-1·40] per 10% increase, p<0·0001) and secondary infections (OR 1·50 [1·22-1·93] per 10% increase, p=0·0005), independent of clinical severity. The three-biomarker tool was validated in five external cohorts of varying infections, severities, and care settings (n=1191). Reanalysis of the CAPE COD trial showed that hydrocortisone conferred a survival benefit only in participants classified as severely dysregulated by our model (30-day mortality: DIP3 OR 0·25 [0·05-0·85], p=0·042; cDIP ≥0·63 OR 0·21 [0·10-0·72], p=0·011), accompanied by faster immune recovery (time × treatment interaction, p<0·0001). No such effect modification was observed when stratifying participants by clinical severity.

INTERPRETATION: We have provided a publicly available three-biomarker framework to determine the extent of host response dysregulation with potential value for precision-guided immunomodulatory therapy.

FUNDING: EU Horizon 2020.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Michels EHA, Dequin PF, Butler JM, et al. Quantifying immune dysregulation in pneumonia and sepsis with a parsimonious machine-learning model: a multicohort analysis across care settings and reanalysis of a hydrocortisone randomised controlled trial. Lancet Respir Med. 2026. PMID: 41856148. doi:10.1016/S2213-2600(25)00429-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。